The Paris Technology and Life Sciences team advised Bpifrance, Sofinnova Partners and Balestier in the $40 million fundraising of Limflow.
New investors Longitude Capital, Soleus Capital Management and an undisclosed strategic investor joined the round. Existing major shareholders Sofinnova Partners, Bpifrance, the French sovereign investment bank and Balestier also participated in the round.
Paris-based LimFlow develops the LimFlow system for minimally invasive treatment of chronic limb-threatening ischemia (CLTI), a severe form of peripheral artery disease (PAD). The system uses a family of transcatheter products designed to optimize the perfusion of the critically ischemic foot to potentially avoid major amputation, resolve pain and promote wound healing.
The Goodwin team was led by Anne-Charlotte Rivière and included as well as Marie Fillon and Louis de Chezelles on IP aspects.